anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a medicine which is used for treating malignant tumors. The present invention comprises components of pine pollen, bamboo leaf essence, oldenlandia diffusa, paris root and glossy privet fruit, wherein the pine pollen and the bamboo leaf essence are soaked in dry red wine, and the oldenlandia diffusa, the paris root and the glossy privet fruit are decocted by adopting water. The constituents comprises the medicines of the following percentage by weight: 2.3% to 2.5% of the pine pollen, 0.14% to 0.2% of the bamboo leaf essence and the dry red wine as the rest. 3% to 4% of the oldenlandia diffusa, 0.67% to 1.3% of the paris root, 2% of the glossy privet fruit and water as the rest. The present invention aims to reduce the morbidity of cancer and improve the cure rate of cancer, and the pine bamboo wine in the prescription is functional health care wine, which is used for preventing cancer. When a person is afflicted with cancer, the person can take the present invention orally, the present invention performs the functions of preventing and curing cancer, and the effect is significant. The present invention plays a positive and significant role in preventing, resisting, treating cancer and relieving cancer pain.
The management of hypertrophic scars (HSs), characterized by excessive collagen production, involves various nonsurgical and surgical interventions. However, the absence of a well-defined molecular mechanism governing hypertrophic scarring has led to less-than-ideal results in clinical antifibrotic treatments. Therefore, our study focused on the role of decorin (DCN) and its regulatory role in the TGF-β/Smad signalling pathway in the development of HSs. In our research, we observed a decrease in DCN expression within hypertrophic scar tissue and its derived cells (HSFc) compared to that in normal tissue. Then, the inhibitory effect of DCN on collagen synthesis was confirmed in Fc and HSFc via the detection of fibrosis markers such as COL-1 and COL-3 after the overexpression and knockdown of DCN. Moreover, functional assessments revealed that DCN suppresses the proliferation, migration and invasion of HSFc. We discovered that DCN significantly inhibits the TGF-β1/Smad3 pathway by suppressing TGF-β1 expression, as well as the formation and phosphorylation of Smad3. This finding suggested that DCN regulates the synthesis of collagen-based extracellular matrix and fibrosis through the TGF-β1/Smad3 pathway.
OBJECTIVE: Seizures can be difficult to control in infants and toddlers. Seizures with periods of apnea and hypoventilation are common following severe traumatic brain injury (TBI). We previously observed that brief apnea with hypoventilation (A&H) in our severe TBI model acutely interrupted seizures. The current study is designed to determine the effect of A&H on subsequent seizures and whether A&H has potential therapeutic implications.
METHODS: Piglets (1 week or 1 month old) received multifactorial injuries: cortical impact, mass effect, subdural hematoma, subarachnoid hemorrhage, and seizures induced with kainic acid. A&H (1 min apnea, 10 min hypoventilation) was induced either before or after seizure induction, or control piglets received subdural/subarachnoid hematoma and seizure without A&H. In an intensive care unit, piglets were sedated, intubated, and mechanically ventilated, and epidural electroencephalogram was recorded for an average of 18 h after seizure induction.
RESULTS: In our severe TBI model, A&H after seizure reduced ipsilateral seizure burden by 80% compared to the same injuries without A&H. In the A&H before seizure induction group, more piglets had exclusively contralateral seizures, although most piglets in all groups had seizures that shifted location throughout the several hours of seizure. After 8-10 h, seizures transitioned to interictal epileptiform discharges regardless of A&H or timing of A&H.
SIGNIFICANCE: Even brief A&H may alter traumatic seizures. In our preclinical model, we will address the possibility of hypercapnia with normoxia, with controlled intracranial pressure, as a therapeutic option for children with status epilepticus after hemorrhagic TBI.
Risk Summary

Limited data from published literature report the presence of Zolpidem in human milk. There are reports of excess sedation in infants exposed to Zolpidem through breastmilk [see Clinical Considerations]. There is no information on the effects of Zolpidem on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Zolpidem Tartrate Tablets and any potential adverse effects on the breastfed infant from Zolpidem Tartrate Tablets or from the underlying maternal condition.

Clinical Considerations

Infants exposed to Zolpidem Tartrate Tablets through breastmilk should be monitored for excess sedation, hypotonia, and respiratory depression. A lactating woman may consider interrupting breastfeeding and pumping and discarding breast milk during treatment and for 23 hours (approximately 5 elimination half-lives) after Zolpidem Tartrate Tablets administration in order to minimize drug exposure to a breast fed infant.
Patients receive bortezomib, rituximab, and bendamustine hydrochloride as patients in arm B. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to arm H.
PROBLEM TO BE SOLVED: To provide a quickly preparable and low-risk method for preparing hydrogel comprising an injectable thiol group, and to provide a hydrogel preparation kit, and to provide a use of hydrogel and a method thereof.SOLUTION: Hydrogel is prepared by binding (a) a water soluble polymer containing a thiol group to (b) a water soluble metal salt in an aqueous solution. Hydrogel can be prepared quickly to be used as blood vessel sealant, a vessel closing device or a drug delivery carrier. Preferably, AuClis used as a metal salt. As a water soluble polymer, Polysaccharide, gelatin, cellulose, starch, lipid, albumin, collagen, polylysine, or the like is used. The water soluble polymer comprises polyethylene glycol comprising at least four branches. The hydrogel is biodegradable and is prepared in less than about 60 seconds.
Amiloride hydrochloride, an antikaliuretic-diuretic agent, is a pyrazine-carbonyl-guanidine that is unrelated chemically to other known antikaliuretic or diuretic agents. It is the salt of a moderately strong base (pKa 8.7). It is designated chemically as 3,5-diamino-6-chloro-N-(diaminomethylene) pyrazinecarboxamide monohydrochloride, dihydrate and has a molecular weight of 302.12. Its molecular formula is C 6H 8CIN 7O•HCl•2H 2O and its structural formula is: 

Amiloride hydrochloride is a pale-yellow to greenish-yellow powder. It is freely soluble in dimethylsulphoxide; slightly soluble in water, ethyl alcohol and isopropyl alcohol; sparingly soluble in methyl alcohol; practically insoluble in acetone, chloroform, diethyl ether and ethyl acetate.

Each amiloride hydrochloride tablet intended for oral administration contains 5 mg of amiloride hydrochloride, calculated on the anhydrous basis. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, D&C yellow #10 aluminum lake, dibasic calcium phosphate dihydrate, FD & C yellow #6 aluminum lake, magnesium stearate, microcrystalline cellulose and povidone.
Systems and methods to identify new protein targets of a chemical compound or its derivatives were described. The methods can be used for detection of new binding partners as long as the chemical compound can covalently bind to the protein targets. Once protein targets are resolved, information related to new protein targets can then be used to couple with real-world patient data such as adverse events, efficacy data, and disease correlation data to deduce real-world evidence. Systems collectively with all this information can aide clinical development and use of pharmaceutical drug. Methods are provided for detection of covalently bound phenyl vinyl sulfone (PVS) or its derivatives, and afatinib or its derivatives. Furthermore, generation of antiserum recognizing carrier bound PVS or carrier bound afatinib is described. PRMT1 is described as a new target of PVS and RRM1, RRM2, and NFKB are described as new targets of afatinib.
A spinal cord injury (SCI) disrupts the communication within the nervous system, leading to limitations in sensorimotor activities, such as walking. These limitations are associated with muscle weakness, a disturbance of the reflex activity, and the inability or difficulty to recruit muscles below the lesion. Regular use of functional electrical stimulation (FES) can result in recovery of voluntary muscle control and muscle strength. Studies that investigated the effect of locomotor training on a treadmill with functional electrical stimulation and/or body weight support (BWS) show improved function of the lower limbs. FES-assisted gait therapy may be a promising method for improving gait function in individuals with an incomplete SCI. Therefore, this study will investigate if an FES-assisted gait (with BWS) is feasible and safe. This study will also investigfate if an FES-assisted gait can improve gait function in people with an incomplete SCI.

Primary objective of this pilot study is to assess the feasibility and safety of an FES-assisted gait training intervention. The secondary objectives are to assess the effects of an FES-assisted gait training intervention on gait function.
Within a cycle of 28 days, participants received a loading dose of PKC412 100 mg bid on days 1-2, followed by PKC412 50 mg bid for 3 weeks from days 3-21. On day 22, itraconazole 100 mg bid was added to the treatment regimen. The combinations of PKC412 and Itraconazole continued until disease progression, unacceptable toxicity, or withdrawal of consent.
A method and systems for determining an early warning score for a health status of a patient are provided. An example method includes acquiring, during a predetermined time period via sensors integrated into a wearable device worn on a wrist of the patient, initial values of medical parameters of patient. The medical parameters include a respiratory rate, oxygen saturation, temperature, blood pressure, and pulse rate, and level of consciousness. The method includes determining, based on the initial values, normal values of the medical parameters. The method includes acquiring, via the sensors and at a pre-determined frequency, further values of the medical parameters. The method includes determining, based on deviations of the further values from the normal values, individual scores for the medical parameters. The method includes calculating, based on the individual scores, a general score. The method includes determining, based on the general score, the health status of the patient.
Participants who have never been pregnant will complete 2 experimental sessions, separated by 7-10 days. Participants will complete multiple questionnaires, maximal voluntary contractions of the lower extremity muscles, clinical tests of lumbopelvic neuromuscular control/posterior pelvic pain provocation, and fatiguing lower extremity/trunk muscle exercise. Ultrasound imaging will be performed to measure inter-recti distance. Wireless EMG sensors will be used to record EMG and limb steadiness (via IMUs). Physical activity will be measured by questionnaire and accelerometer.
Typical pathogenic bacteria of the genus Bordetella cause respiratory diseases, many of which are characterized by severe coughing in host animals. In human infections with these bacteria, such as whooping cough, coughing imposes a heavy burden on patients. The pathophysiology of this severe coughing had long been uncharacterized because convenient animal models that reproduce Bordetella-induced cough have not been available. However, rat and mouse models were recently shown as useful for understanding, at least partially, the causative factors and the mechanism of Bordetella-induced cough. Many types of coughs are induced under various physiological conditions, and the neurophysiological pathways of coughing are considered to vary among animal species, including humans. However, the neurophysiological mechanisms of the coughs in different animal species have not been entirely understood, and, accordingly, the current understanding of Bordetella-induced cough is still incomplete. Nevertheless, recent research findings may open the way for the development of prophylaxis and therapeutic measures against Bordetella-induced cough.
Participants performed muscle relaxation exercises at least 4 times a week for 6 weeks. Once a week, the researcher exercised with the participants in online groups to control the research and to check whether the participants were doing the exercise correctly.
The etiology of cerebral venous sinus thrombosis (CVST) is multifactorial. Although many acquired and genetic factors have been recognized as risk factors, hyperhomocysteinemia (hHcy) is independently associated with CVST. We describe three cases of CVST in this case series. All of them presented with headache. Two patients had papilledema and visual disturbances. On evaluation, there was CVST, and prothrombotic workup showed hHcy. In addition, two of them reported very low Vitamin B12 levels. All of them were treated with low-molecular-weight heparin followed by oral anticoagulation and Vitamin B6, B9, and B12 supplements. All of them responded to treatment, and follow-up imaging studies in two of them showed resolution of thrombosis. hHcy should be considered in the evaluation of CVST, especially in the setting of a pure vegetarian diet. Fortification of the diet with Vitamin B12 may be considered the majority of Indians consume predominantly vegetarian food.
An anhydrous cosmetic composition for controlling body odour or underarm wetness, wherein the composition contains a particulate agent to combat odour or underarm wetness and 2-Ethyl-1,3-hexanediol as solvent. The particulate agent may be an aluminium salt (e.g. aluminium chlorohydrate) as an agent against underarm wetness. The particulate agent may be sodium bicarbonate. The composition may further comprise an organic carrier such as liquid paraffin oil, isodecane, linear silicone oils etc. The anhydrous composition may comprise a thickener (e.g. silica silylate) or a hydrophobically modified clay mineral such as disteardimonium hectorite. Preferably, the composition comprises 3-40 wt.% of an aluminium salt. The composition may comprise 1-25 wt.% of etohexadiol. The cosmetic product may be mixed with a hydrocarbon propellant. The product can be used with a roll-on applicator. Also claimed is the use of an anhydrous cosmetic composition as described for controlling body odour and/or underarm wetness.
The present disclosure is directed to a skin protectant formulation that is designed to be sprayed onto human skin for the purpose of protecting the skin. In particular, an exemplary formulation of the present disclosure contains at least a carrier, a structurant and a skin protectant agent. An exemplary formulation contains a carrier comprising at least water, a structurant comprising at least a laponite clay, and a skin protectant agent comprising petrolatum. Typically, the skin protectant formulation will comprise at least about 30 wt. % of a skin protectant agent. A continuous spray dispenser may be used to apply the skin protectant formulation to reduce the need for rubbing as the treated area can be covered by a mist of the skin protectant formulation requiring no need to rub for application or small droplets that do not require extensive time for rubbing in.
BACKGROUND: The KangDuo surgical robot (KD-SR-01) was recently developed in China. This study aims to evaluate the short-term outcomes of KD-SR-01 for colorectal cancer surgery.
METHODS: This is a multicentre randomised controlled noninferiority trial conducted in three centers in China. Enrolled patients were randomly assigned at a 1:1 ratio to receive surgery using the KD-SR-01 system (KD group) or the da Vinci Xi (DV) robotic system (DV group). The primary endpoint was the success rate of operation. The second endpoints were surgical outcomes, pathological outcomes, and postoperative outcomes.
RESULTS: Between July 2022 and May 2023. A total of 100 patients were included in the trial and randomly assigned to the KD group (50 patients) and the DV group (50 patients). All cases were completed successfully without conversion to laparoscopic surgery. The time to flatus and the incidence of postoperative complications of Clavien-Dindo grade II or higher grade were comparable between the two groups. Surgeons reported a high level of comfort with the KD-SR-01 system. In the subgroup analysis of different operative procedures, there were no significant differences in docking time, console time, blood loss, and the length of the incision for extraction between the two groups. There were no differences in pathological outcomes including maximum tumor diameter, circumferential resection margin, distal resection margin, and number of harvested lymph nodes.
CONCLUSIONS: The KD-SR-01 system was a viable option for colorectal cancer robotic surgery, with acceptable short-term outcomes comparable to the da Vinci Xi robotic system.
PURPOSE OF REVIEW: Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) are both significant burdens on the healthcare system and often coexist. Mechanistic links between the two conditions and their clinical impact are increasingly understood.
RECENT FINDINGS: Recent studies demonstrate multiple mechanisms by which the pathobiology of COPD may have negative effects on the cardiovascular system. These include extrapulmonary consequences of the COPD inflammatory state, cardiac autonomic dysfunction, which has been recently implicated in worsening respiratory symptoms and exacerbation risk, and mechanical effects of lung hyperinflation on left ventricular diastolic function.Clinical studies have consistently shown a high prevalence of CVD in COPD patients and worsened outcomes (and vice versa ). Exacerbations of COPD have also been demonstrated to dramatically increase the risk of cardiovascular events. While some safety concerns exist, medications for COPD and cardiovascular disease should be used in accordance with respective guidelines. However, real-world data show suboptimal management for patients with COPD and CVD.
SUMMARY: COPD and cardiovascular disease have complicated interrelationships. Further mechanistic studies may lead to defining better targets for interventions. Education for medical professionals and implementation of novel screening protocols should be encouraged to fill in the gaps in clinical care for these patients.
In addition to medication using SSRIs, patients will be also treated with games that can regulate emotions. Details are not yet decided. Treatment will last 4 weeks.
The control group performs 3 exercises of stretching and balance during one minute each and three sets. One minute of resting time between sets.
The study is formally endorsed by the Dutch Society of Lung Surgery (NVvL), the Dutch Society of Cardiothoracic Surgery (NVT), the Dutch Society of Radiation Oncology (NVRO). The main objective of the proposed randomized trial is to compare efficacy of SABR to the efficacy of metastasectomy with regards to the primary endpoint (local recurrence free survival at 5 years) in patients with limited colorectal pulmonary metastases. This will determine the most effective local treatment modality. The investigators hypothesize that patients with limited colorectal pulmonary metastases will have non-inferior overall survival after pulmonary metastasectomy compared to SABR, however metastasectomy will result in superior local recurrence free survival at five years when compared to SABR. In addition, the investigators hypothesize that SABR is associated with lower morbidity, comparable quality of life and comparable health care costs compared to metastasectomy. Recurrent metastases are preferably treated by the index treatment to which the patient was randomized, local recurrent metastases are preferably treated by means of cross-over between both arms. Comparing metastasectomy to SABR for patients with colorectal pulmonary metastases will present the international community the evidence needed to better select patients for local radical treatment, while diminishing uncertainty for patients and care givers.
PURPOSE: A method for surface treating magnetic particles and a magnetic composite prepared by the same are provided to enable mass production of the magnetic composite and to enhance safety thereof. CONSTITUTION: A method for surface treating magnetic particles comprises: a step of mixing a surface precursor containing a alkoxy group- and amine group-substituted silicone with a solvent to prepare a surface treatment(a); and a step of mixing magnetic particles with a hydroxy group(-OH) with surface treatment and surface treating the magnetic particles with silicone oxide containing amine groups(b). The amine group includes a monoamine group, diamine group, triamine group, ethylene diamine, or diethylene triamine. The magnetic particles are magnetite(Fe_3O_4), hematite(alpha-Fe_2O_3), or maghemite(gamma-Fe_2O_3). The surface precursor contains aminopropyltriethoxy-silane. [Reference numerals] (a) Preparing a surface treatment agent; (AA) Start; (b-1) Treating magnetic particles with acid; (b-2) Mixing the acid-treated particles with a water soluble solvent; (b-3) Mixing with the surface treatment agent; (BB) End
During the First Intervention (8 weeks), subjects will be provided with daily 20 mg of olmesartan for the first 2 weeks. Subjects receive additional daily doses of 40 mg olmesartan for the remainder of the study period (6 weeks). The dose remains at 20 mg per day, however, if BP falls below 110/70 during the first 2 weeks. In addition, subjects will continue taking the drug during the 2-week follow-up testing period. Subjects will then proceed to the Washout period (2 weeks). During the Second Intervention (8 weeks), no drug will be administered to the subjects.
Pretreatment with currettage. Metvix cream. Daylight PDT. Application of Cicaplast to test area immediately after dPDT. Cicaplast application twce daily for 14 days.
OBJECTIVE: We aimed to examine the relationship between chronic rhinosinusitis without nasal polyps and microplastics.
METHODS: A total of 80 patients participated in this prospectively planned study. The patients were divided into two groups. Group 1 had 50 patients with chronic rhinosinusitis without nasal polyps, whereas Group 2 had 30 healthy volunteers. The age and gender of the participants were noted. Nose Obstruction Symptom Evaluation questionnaire was applied to the patients. The patients performed nasal lavage with saline. Microplastics were examined in the collected nasal lavage fluids, and their numbers were noted. The groups were compared on these values.
RESULTS: The mean age was 38.06 ± 14.15 years in the chronic rhinosinusitis group without nasal polyps and 33.60 ± 11.68 years in the control group. There was no significant difference between the groups in terms of age and gender. There was a significant difference in the number of microplastics between the chronic rhinosinusitis group without nasal polyps and the control group (p < 0.001). Microplastics were detected in all participants.
CONCLUSIONS: We found more microplastics in patients with chronic rhinosinusitis without nasal polyps. According to this result, we can say that there may be a relationship between chronic rhinosinusitis and microplastics.
LEVEL OF EVIDENCE: 3 Laryngoscope, 134:1077-1080, 2024.